Bellerophon Therapeutics Inc. (BLPH) to Post FY2016 Earnings of ($1.76) Per Share, FBR & Co Forecasts
Bellerophon Therapeutics Inc. (NASDAQ:BLPH) – Analysts at FBR & Co lifted their FY2016 earnings estimates for shares of Bellerophon Therapeutics in a research report issued to clients and investors on Tuesday. FBR & Co analyst C. James now anticipates that the brokerage will post earnings of ($1.76) per share for the year, up from their previous estimate of ($1.85). FBR & Co also issued estimates for Bellerophon Therapeutics’ Q4 2016 earnings at ($0.31) EPS, FY2017 earnings at ($1.36) EPS and FY2018 earnings at ($1.31) EPS.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.12.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 15th. Cowen and Company restated a “buy” rating on shares of Bellerophon Therapeutics in a report on Thursday, August 11th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 0.86 on Thursday. Bellerophon Therapeutics has a one year low of $0.86 and a one year high of $4.58. The firm has a 50-day moving average of $1.31 and a 200-day moving average of $1.57. The company’s market cap is $12.56 million.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.